Background The Monitored Atherosclerosis Regression Study, a randomized, double-blind, placebo-controlled, 2-year trial of lovastatin monotherapy, found that coronary lesions <50% diameter stenosis (%S) and coronary lesions .50%S at baseline had different responses to therapy. We now report on clinical, lipid, and nonlipid risk factors of treatment response in these lesion subsets.
Methods and Resuls Two hundred seventy subjects, 37 to 67 years old, with plasma total cholesterol (TC) 190 to 295 mg/dL (4. 91 to 7.63 mmol/L) and total triglyceride <500 mg/dL (5.65 mmol/L) were randomized to low-fat, low-cholesterol diet and either lovastatin 80 mg/d or placebo. Logistic regression was used to model the association between risk factors and coronary lesion progression in mild/moderate (<50%S) and severe (250%S) lesions in 220 angiogram pairs analyzed by computer quantitative coronary angiography. In the placebo group, risk factors (P<.05) for the progression of mild/moderate lesions were triglycerides and TC/high-density lipoprotein cholesterol (HDL-C). Risk factors for the progression of severe lesions were HDL-C (negative), low-density lipoprotein cholesterol (LDL-C)/HDL-C, and TC/HDL-C. TC/HDL-C was the pre-T X ahe Monitored Atherosclerosis Regression Study (MARS) was a double-blind, 2-year, placebocontrolled, randomized coronary angiographic trial that tested reduction of low-density lipoprotein cholesterol (LDL-C) using lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.' The two angiographic outcomes in MARS were the per-subject change in percent diameter stenosis (%S) as measured by quantitative coronary angiography (QCA) (primary end point) and the global change score, a consensus opinion of angiographic change as determined by panels of blinded expert human readers (secondary end point). The mean global change score was +0.9 (indicating progression) in the placebo group and +0.4 in the lovastatin group (P<.01); 13 placebo versus 28 lovastatin subjects had global change scores indicating regression (P=.02). Conversely, no statistical differences were found in the overall change in %S between treatment groups as measured by QCA: %S increase of +2.2% for the placebo group versus +1.6% for the lovastatin group (P=NS). However, benefit due to lovastatin was seen for severe (>50%S) lesions at baseline (%S increase of +0.9% for the placebo group versus %S decrease of -4.1% for the lovastatin group, P<.01) but not for mild/moderate lesions (<50%S) at baseline (%S increase of +3.0% in the placebo group versus +2.6% in the lovastatin group, NS). An external Data and Safety Monitoring Committee recommended against further continuation of an optional 2-year extension of MARS, primarily on the basis of the observed treatment benefit in the global change score end point and the QCA end point for lesions >50%. 
Methods

MARS Design
The MARS design has been described in detail."9 In brief, 270 subjects (91% men) 37 to 67 years old (average, 58 years) with plasma total cholesterol 190 to 295 mg/dL (4.91 to 7.63 mmol/L) and angiographically defined coronary artery disease (in at least two segments with at least one segment narrowed by at least 50%S and unaltered by percutaneous transluminal coronary angioplasty) were randomized to cholesterol-lowering diet and either lovastatin 80 mg/d or placebo. Treatment groups had identical dietary targets for cholesterol and fat intake (daily cholesterol intake .250 mg; .27% of calories as fat, with saturated fat constituting .7% of total calories; and monounsaturated and polyunsaturated fats .10% of calories each).
Baseline and 2-year follow-up coronary angiograms were completed by 247 subjects (23 subjects did not have a second angiogram for medical or personal reasons). The percutaneous femoral technique was used, and sufficient right and left anterior oblique views were obtained to demonstrate all lesions clearly.9 QCA analyses were performed blinded to treatment but not to temporal order.9 Film pairs were processed in tandem with dual projectors to match frames for orientation and degree of contrast filling, and arterial segments were defined from branch to branch. Twenty-three film pairs with nitroglycerin mismatches (eg, nitroglycerin administered at one but not the other angiogram) and 4 film pairs not evaluable by QCA were excluded from QCA analyses, resulting in 220 evaluable angiogram pairs. Three sequential frames exposed during end diastole were digitized when possible; if 
Statistical Analysis
The two dependent variables were the average per-patient change in %S in mild/moderate lesions (<50%S) at baseline and the average per-patient change in %S in severe lesions (.50%S) at baseline. Each dependent variable was dichotomized to represent nonprogression (average change in %S .0) or progression (average change in %S >0). Independent variables included on-trial values and changes from baseline in clinical factors (age, smoking status, fasting glucose, systolic and diastolic blood pressures, pulse rate, and percent ideal body weight); lipids (TC, HDL-C, LDL-C, triglycerides, and the ratios TC/HDL-C and LDL-C/HDL-C); and apoplipoproteins (A-I, B, E, C-III-whole serum, C-III-heparin supernatant, C-III-heparin precipitate, and the ratio of C-Illheparin supernatant to C-III-heparin precipitate). On-trial values were calculated as the average over all visits weighted by the interval between visits; changes were computed as the on-trial weighted average minus the baseline average.
All analyses were carried out within each treatment group. Associations between independent and dependent variables were assessed by univariate and stepwise multiple logistic regression. For The two treatment groups were not significantly different at baseline for any of the lipids, lipoproteins, (Table 1) . Compared with the placebo group, the lovastatintreated group showed significantly greater on-trial decreases in diastolic blood pressure (P<.03), TC, LDL-C, TC/HDL-C, LDL-C/HDL-C, triglycerides, apo B, apo E, and apo C-Ill (whole serum and heparin precipitate), all P<.001. The lovastatin group also showed significantly greater increases in HDL-C and the ratio of apo C-III-heparin supernatant to C-IIIheparin precipitate (P<.001). There were no treatment differences in apo A-I. Although triglyceride levels decreased on average by 22% in the lovastatin-treated group, triglyceride and apo C-III levels increased in 14% and 31% of the lovastatin subjects, respectively. Baseline Angiographic Characteristics and On-Trial Changes Baseline-2-year film pairs were evaluable by QCA for 1893 lesions in 220 subjects. There were no significant treatment group differences at baseline either in the distribution of mild/moderate or severe lesions or in the average %S. The majority (n=1569, 83%) of lesions were <50%S at baseline. Table 2 . RR estimates >1 indicate that high levels of the independent variable are associated with coronary progression, while RR estimates <1 indicate that high levels of the independent variable are associated with coronary nonprogression. Multivariate logistic regression models are presented in Table 3 . Placebo Group
In the placebo group, univariate risk factors for progression of mild/moderate baseline lesions were (Table 2) were absolute increases in systolic blood pressure, apo C-IIIheparin precipitate, and on-trial triglyceride and apo C-Ill (both whole serum and heparin precipitate). In the multivariate model, the on-trial level of apo C-III- (Table 3) . For severe lesions 250%S at baseline, only cholesterol-rich lipoproteins or their markers (HDL-C, LDL-C/HDL-C, and TC/HDL-C) were significant univariate risk factors for progression in the placebo group (Table 2) . Unlike the situation with lesions <50%S, aggressive LDL-C and TC lowering did not alter cholesterol-rich lipoproteins or their markers (LDL-C, apo B, LDL-C/HDL-C, and TC/HDL-C) as the predictors of progression of lesions 250%S in the lovastatin group.
In the multivariate analyses, TC/HDL-C emerged as the single risk factor for both mild/moderate and severe lesion progression in the placebo group; LDL-C/ HDL-C was the single significant risk factor for progression of severe lesions in the lovastatin group (Table 3) . These findings are consistent with the NHLBI Type II Coronary Intervention Study, which, with placebo and treatment groups combined, demonstrated TC/HDL-C and LDL-C/HDL-C ratios as the predominant risk factors for progression of lesions 250%S. Risk factor relations to lesions <50%S were not reported.2 The St Thomas' Atherosclerosis Regression Study (STARS)5 and the Leiden Intervention Trial21 also reported the TC/HDL-C ratio as the predominant risk factor for lesion progression. However, risk factor relations were not determined within treatment groups or by lesion size. The Framingham observational study has additionally demonstrated the importance of the TC/HDL-C ratio as a risk factor for the development of coronary heart disease.22 As shown in Table 3 , the risk of progression in either group was greatest for the upper quartile of the distributions of TC/HDL-C (placebo group, mild/moderate, or severe lesions) and LDL-C/ HDL-C (lovastatin group, severe lesions).
Multivariate analysis demonstrated apo C-III-heparin precipitate to be the predominant risk factor driving lesions <50%S toward progression once LDL-C was aggressively reduced. As shown in Table 3 Our risk factor analyses from MARS, which extend previous findings of CLAS,8 indicate that triglyceriderich lipoproteins play an important role in progression of lesions <50%S in subjects treated with aggressive LDL-C lowering. These results are the first to indicate that lipoproteins have an important differential effect on lesion progression according to lesion size. Since triglyceride-rich lipoproteins are a significant risk factor for driving lesions <50%S toward progression, they need attention in addition to LDL-C in the treatment of atherosclerosis.
